Haemonetics Corporation (HAE) is a Healthcare stock trading at $106.35 (as of 2026-08-20), with a market capitalization of $4.84B and a trailing P/E of 32.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Haemonetics provides medical products and solutions for plasma and blood collection, including automated plasma collection devices, related disposables, and donor management software, plus hospital products, and it makes money by selling these devices, disposables, and software solutions to plasma customers and hospitals.
Haemonetics combines automated collection equipment with related disposables and software platforms for plasma customers, plus hospital offerings, so sales come from a mix of devices, disposables, and IT-enabled solutions across its Plasma, Blood Center, and Hospital segments.
| Plasma | $0.1B |
| Blood Ctr | $0.1B |
| Hospital | $0.1B |
Business quality (Mixed): The company has a straightforward three-segment structure (Plasma, Blood Center, Hospital) and reports both gross margin and operating margin, while its most visible operating measures are concentrated in plasma-related revenue and market-position metrics.
Valuation: At 36× earnings, HAE trades 12% above the Medical Equipment average (32×). Note: one-time items can distort reported P/E.
| Price | $106.35 |
| Market Cap | $4.84B |
| P/E Ratio | 32.2 |
| EV / EBITDA | 16.6 |
| Price / Book | 5.78 |
| Price / Sales | 3.65 |
| FCF Yield | 8.0% |
| DCF Value (model) | $4.07 |
| DCF Upside vs Price | -96.2% |
| Revenue (TTM) | $1.33B |
| Net Margin | 7.3% |
| Revenue Growth (YoY) | -2.0% |
| EPS Growth (YoY) | -38.1% |
| FCF Growth (YoY) | 82.8% |
| Altman Z-Score | 3.03 (safe) |
| Piotroski F-Score | 7/9 (strong) |
| Stock P/E | 32.2 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Medical Equipment) | 32.9 |
| vs Sector | 48.9% |
| vs Industry | -2.2% |
| Top Institutional Holder | VANGUARD GROUP INC ($381.60M) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 3 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | Christopher A. Simon |
| Employees | 3,657 |
| Country | US |
| IPO Date | 1991-05-10 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.